Minireview: Challenges and opportunities in development of PPAR agonists.

The clinical impact of the fibrate and thiazolidinedione drugs on dyslipidemia and diabetes is driven mainly through activation of two transcription factors, peroxisome proliferator-activated receptors (PPAR)-α and PPAR-γ. However, substantial differences exist in the therapeutic and side-effect profiles of specific drugs. This has been attributed primarily to the complexity of drug-target complexes that involve many coregulatory proteins in the context of specific target gene promoters. Recent data have revealed that some PPAR ligands interact with other non-PPAR targets. Here we review concepts used to develop new agents that preferentially modulate transcriptional complex assembly, target more than one PPAR receptor simultaneously, or act as partial agonists. We highlight newly described on-target mechanisms of PPAR regulation including phosphorylation and nongenomic regulation. We briefly describe the recently discovered non-PPAR protein targets of thiazolidinediones, mitoNEET, and mTOT. Finally, we summarize the contributions of on- and off-target actions to select therapeutic and side effects of PPAR ligands including insulin sensitivity, cardiovascular actions, inflammation, and carcinogenicity.

[1]  Zuyi Yuan,et al.  Peroxisome proliferation-activated receptor-gamma ligands ameliorate experimental autoimmune myocarditis. , 2003, Cardiovascular research.

[2]  R. Evans,et al.  PPAR-γ dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation , 2001, Nature Medicine.

[3]  R. Heyman,et al.  Three amino acids specify coactivator choice by retinoid X receptors. , 2000, Molecular endocrinology.

[4]  G. Schroth,et al.  Differences in hepatotoxicity and gene expression profiles by anti-diabetic PPAR γ agonists on rat primary hepatocytes and human HepG2 cells , 2006, Molecular Diversity.

[5]  S. Kato,et al.  Ligand type-specific interactions of peroxisome proliferator-activated receptor γ with transcriptional coactivators. , 2013, The Journal of Biological Chemistry.

[6]  Jiandie D. Lin,et al.  PGC-1 coactivators in the control of energy metabolism. , 2011, Acta biochimica et biophysica Sinica.

[7]  F. Gonzalez,et al.  Vascular PPARgamma controls circadian variation in blood pressure and heart rate through Bmal1. , 2008, Cell metabolism.

[8]  M. Lazar,et al.  Corepressors selectively control the transcriptional activity of PPARgamma in adipocytes. , 2005, Genes & development.

[9]  Claire Redin,et al.  A Mitochondrial Pyruvate Carrier Required for Pyruvate Uptake in Yeast, Drosophila, and Humans , 2012, Science.

[10]  M. Lazar,et al.  A Potent Antidiabetic Thiazolidinedione with Unique Peroxisome Proliferator-activated Receptor γ-activating Properties* , 1998, The Journal of Biological Chemistry.

[11]  Bruce M. Spiegelman,et al.  Inhibition of Adipogenesis Through MAP Kinase-Mediated Phosphorylation of PPARγ , 1996, Science.

[12]  B. Spiegelman,et al.  Effects of ligand activation of peroxisome proliferator-activated receptor gamma in human prostate cancer. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[13]  P. Widdowson,et al.  The development of overt diabetes in young Zucker Diabetic Fatty (ZDF) rats and the effects of chronic MCC‐555 treatment , 1998, British journal of pharmacology.

[14]  Sukjoon Yoon,et al.  1,3-Diphenyl-1H-pyrazole derivatives as a new series of potent PPARγ partial agonists. , 2010, Bioorganic & medicinal chemistry.

[15]  Su-Lin Lee,et al.  PPARgamma-independent antitumor effects of thiazolidinediones. , 2009, Cancer letters.

[16]  Jichun Yang,et al.  PPAR&ggr; as a therapeutic target in diabetic nephropathy and other renal diseases , 2012, Current opinion in nephrology and hypertension.

[17]  Alberto Zambon,et al.  Fibrates and future PPARα agonists in the treatment of cardiovascular disease , 2008, Nature Clinical Practice Cardiovascular Medicine.

[18]  Ji Li,et al.  Acute rosiglitazone treatment is cardioprotective against ischemia-reperfusion injury by modulating AMPK, Akt, and JNK signaling in nondiabetic mice. , 2011, American journal of physiology. Heart and circulatory physiology.

[19]  Peter Libby,et al.  Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. , 2002, JAMA.

[20]  S. Fava,et al.  Albuminuria and glomerular filtration rate in type 2 diabetes mellitus. , 2011, Minerva urologica e nefrologica = The Italian journal of urology and nephrology.

[21]  S. Nissen,et al.  Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. , 2007, The New England journal of medicine.

[22]  Quan Liu,et al.  The PPARα/γ dual agonist chiglitazar improves insulin resistance and dyslipidemia in MSG obese rats , 2006 .

[23]  W. Bao,et al.  In Vivo Myocardial Protection From Ischemia/Reperfusion Injury by the Peroxisome Proliferator–Activated Receptor-&ggr; Agonist Rosiglitazone , 2001, Circulation.

[24]  F. D’Acquisto,et al.  Thiazolidinediones are partial agonists for the glucocorticoid receptor. , 2009, Endocrinology.

[25]  J. Colca,et al.  What has prevented the expansion of insulin sensitisers? , 2006, Expert opinion on investigational drugs.

[26]  B. Selling,et al.  Ligand and coactivator recruitment preferences of peroxisome proliferator activated receptor α , 2002, The Journal of Steroid Biochemistry and Molecular Biology.

[27]  P. Poirier,et al.  The cardiovascular effects of peroxisome proliferator-activated receptor agonists. , 2012, The American journal of medicine.

[28]  J. Lehmann,et al.  Peroxisome Proliferator-activated Receptors α and γ Are Activated by Indomethacin and Other Non-steroidal Anti-inflammatory Drugs* , 1997, The Journal of Biological Chemistry.

[29]  B. Staels,et al.  Rosiglitazone, a peroxisome proliferator-activated receptor-gamma, inhibits the Jun NH(2)-terminal kinase/activating protein 1 pathway and protects the heart from ischemia/reperfusion injury. , 2002, Diabetes.

[30]  P. J. Larsen,et al.  Dissociation of antihyperglycaemic and adverse effects of partial perioxisome proliferator-activated receptor (PPAR-gamma) agonist balaglitazone. , 2008, European journal of pharmacology.

[31]  Ajit S. Divakaruni,et al.  A Mitochondrial Mystery, Solved , 2012, Science.

[32]  Y. Will,et al.  The Development of Subcutaneous Sarcomas in Rodents Exposed to Peroxisome Proliferators Agonists , 2012, Toxicologic pathology.

[33]  D. K. Nevin,et al.  Rational targeting of peroxisome proliferating activated receptor subtypes. , 2011, Current medicinal chemistry.

[34]  A. Depaoli,et al.  Selective modulation of PPARγ activity can lower plasma glucose without typical thiazolidinedione side-effects in patients with Type 2 diabetes. , 2011, Journal of diabetes and its complications.

[35]  Su-Lin Lee,et al.  PPAR γ-Independent Antitumor Effects of Thiazolidinediones , 2009 .

[36]  B. P. Kota,et al.  An overview on biological mechanisms of PPARs. , 2005, Pharmacological research.

[37]  S. Mudaliar,et al.  Effect of the dual peroxisome proliferator-activated receptor-α/γ agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study , 2009, The Lancet.

[38]  L. Iversen,et al.  Biomarkers for early effects of carcinogenic dual-acting PPAR agonists in rat urinary bladder urothelium in vivo , 2005, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.

[39]  A. Scheen,et al.  Thiazolidinediones and liver toxicity. , 2001, Diabetes & metabolism.

[40]  C. Bannow,et al.  Identification of a novel mitochondrial protein ("mitoNEET") cross-linked specifically by a thiazolidinedione photoprobe. , 2004, American journal of physiology. Endocrinology and metabolism.

[41]  F. Gregoire,et al.  Selective Modulators of PPAR-γ Activity: Molecular Aspects Related to Obesity and Side-Effects , 2007, PPAR research.

[42]  K. Clarke,et al.  Thiazolidinedione treatment normalizes insulin resistance and ischemic injury in the zucker Fatty rat heart. , 2002, Diabetes.

[43]  M. Carey,et al.  Down-Regulation of prostate-specific antigen expression by ligands for peroxisome proliferator-activated receptor gamma in human prostate cancer. , 2000, Cancer research.

[44]  R. Buckingham,et al.  Therapeutic index for rosiglitazone in dietary obese rats: separation of efficacy and haemodilution , 1999, British journal of pharmacology.

[45]  V. Gebski,et al.  Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study , 2011, Diabetologia.

[46]  C. Greyson,et al.  Thiazolidinedione drugs block cardiac KATP channels and may increase propensity for ischaemic ventricular fibrillation in pigs , 2008, Diabetologia.

[47]  C. Grommes,et al.  The Nonthiazolidinedione Tyrosine-Based Peroxisome Proliferator-Activated Receptor γ Ligand GW7845 Induces Apoptosis and Limits Migration and Invasion of Rat and Human Glioma Cells , 2005, Journal of Pharmacology and Experimental Therapeutics.

[48]  J. Onuchic,et al.  Facile transfer of [2Fe-2S] clusters from the diabetes drug target mitoNEET to an apo-acceptor protein , 2011, Proceedings of the National Academy of Sciences.

[49]  T. Elasy,et al.  Thiazolidinedione Use, Fluid Retention, and Congestive Heart Failure: a consensus statement from the American Heart Association and American Diabetes Association Response to Nesto , 2004 .

[50]  J. Veuthey,et al.  Identification and Functional Expression of the Mitochondrial Pyruvate Carrier , 2012, Science.

[51]  Christopher K. Glass,et al.  The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation , 1998, Nature.

[52]  J. Auwerx,et al.  SRC-1 and TIF2 Control Energy Balance between White and Brown Adipose Tissues , 2002, Cell.

[53]  J. Searcy,et al.  Distinct modulation of voltage‐gated and ligand‐gated Ca2+ currents by PPAR‐γ agonists in cultured hippocampal neurons , 2009, Journal of neurochemistry.

[54]  J. Dixon,et al.  MitoNEET is a uniquely folded 2Fe–2S outer mitochondrial membrane protein stabilized by pioglitazone , 2007, Proceedings of the National Academy of Sciences.

[55]  R. Roberts,et al.  Primary culture model of peroxisome proliferator‐activated receptor γ activity in prostate cancer cells , 2003, Journal of cellular physiology.

[56]  D. McClain,et al.  MitoNEET-driven alterations in adipocyte mitochondrial activity reveal a crucial adaptive process that preserves insulin sensitivity in obesity , 2012, Nature Medicine.

[57]  N. McKenna,et al.  Nuclear receptor coregulators , 2003 .

[58]  M. Lindstrom,et al.  INT131: A Selective Modulator of PPARγ , 2009 .

[59]  B. Lanne,et al.  PPARgamma agonist induced cardiac enlargement is associated with reduced fatty acid and increased glucose utilization in myocardium of Wistar rats. , 2006, European journal of pharmacology.

[60]  Matthias Herz,et al.  Effects of the dual peroxisome proliferator-activated receptor-α/γ agonist aleglitazar on renal function in patients with stage 3 chronic kidney disease and type 2 diabetes: a Phase IIb, randomized study , 2014, BMC Nephrology.

[61]  R. Seger,et al.  MAPK- Kinases as Nucleo-Cytoplasmic Shuttles for PPARγ , 2007, Cell cycle.

[62]  H. Young,et al.  Peroxisome proliferator-activated receptor-γ and its ligands attenuate biologic functions of human natural killer cells , 2004 .

[63]  M. Lazar,et al.  A novel therapy for colitis utilizing PPAR-gamma ligands to inhibit the epithelial inflammatory response. , 1999, The Journal of clinical investigation.

[64]  David M. Thomas,et al.  PPARγ-independent induction of growth arrest and apoptosis in prostate and bladder carcinoma , 2006, BMC Cancer.

[65]  J. Bright,et al.  Peroxisome proliferator-activated receptor-gamma agonists inhibit experimental allergic encephalomyelitis by blocking IL-12 production, IL-12 signaling and Th1 differentiation , 2002, Genes and Immunity.

[66]  R. Phipps,et al.  The nuclear receptor PPAR gamma is expressed by mouse T lymphocytes and PPAR gamma agonists induce apoptosis , 2001, European journal of immunology.

[67]  Samuel M. Cohen,et al.  Rodent Carcinogenicity Profile of the Antidiabetic Dual PPAR α and γ Agonist Muraglitazar , 2007 .

[68]  X. Shen,et al.  Differential activation of peroxisome proliferator-activated receptor-gamma by troglitazone and rosiglitazone. , 2000, Diabetes.

[69]  D. Orloff,et al.  Clinical Proof-of-Concept Study With MSDC-0160, a Prototype mTOT-Modulating Insulin Sensitizer , 2013, Clinical pharmacology and therapeutics.

[70]  Rony Seger,et al.  The Ras Inhibitors Caveolin-1 and Docking Protein 1 Activate Peroxisome Proliferator-Activated Receptor γ through Spatial Relocalization at Helix 7 of Its Ligand-Binding Domain , 2011, Molecular and Cellular Biology.

[71]  W. Ahmad.  Effect of Aleglitazar on Cardiovascular Outcomes After Acute Coronary Syndrome in Patients With Type 2 Diabetes Mellitus The AleCardio Randomized Clinical Trial , 2014 .

[72]  B. Zinman,et al.  Rosiglitazone Decreases C-Reactive Protein to a Greater Extent Relative to Glyburide and Metformin Over 4 Years Despite Greater Weight Gain , 2009, Diabetes Care.

[73]  R. Phipps,et al.  Human B Lymphocytes and B Lymphomas Express PPAR-γ and Are Killed by PPAR-γ Agonists , 2002 .

[74]  B. Staels,et al.  Fibrates, Glitazones, and Peroxisome Proliferator–Activated Receptors , 2010, Arteriosclerosis, thrombosis, and vascular biology.

[75]  R. Pola,et al.  Endothelial progenitor cells and angiogenesis join the PPARty. , 2008, Circulation research.

[76]  Robert Bigelow,et al.  Results of a reevaluation of cardiovascular outcomes in the RECORD trial. , 2013, American heart journal.

[77]  R. Ross,et al.  Position Statement Identification and Management of Cardiometabolic Risk in Canada: A Position Paper by the Cardiometabolic Risk Working Group (Executive Summary) , 2011 .

[78]  R. Evans,et al.  Peroxisome Proliferator-Activated Receptor-γ-Deficient Heterozygous Mice Develop an Exacerbated Neural Antigen-Induced Th1 Response and Experimental Allergic Encephalomyelitis 1 , 2003, The Journal of Immunology.

[79]  D. Feinstein,et al.  Inhibition of in Vivo Glioma Growth and Invasion by Peroxisome Proliferator-Activated Receptor γ Agonist Treatment , 2006, Molecular Pharmacology.

[80]  K. Büssow,et al.  Amorfrutins are potent antidiabetic dietary natural products , 2012, Proceedings of the National Academy of Sciences.

[81]  E. Bruckert,et al.  Effects of the New Dual PPARα/δ Agonist GFT505 on Lipid and Glucose Homeostasis in Abdominally Obese Patients With Combined Dyslipidemia or Impaired Glucose Metabolism , 2011, Diabetes Care.

[82]  D. Panigrahy,et al.  Therapeutic potential of thiazolidinediones as anticancer agents , 2003, Expert opinion on investigational drugs.

[83]  T. Aoki.  Current Status of Carcinogenicity Assessment of Peroxisome Proliferator-Activated Receptor Agonists by the US FDA and a Mode-of-Action Approach to the Carcinogenic Potential , 2007 .

[84]  任艳,et al.  胰岛素增敏剂一Thiazolidinediones研究现状 , 2000 .

[85]  B. Klein,et al.  Global Prevalence and Major Risk Factors of Diabetic Retinopathy , 2012, Diabetes Care.

[86]  G. Schwartz,et al.  Troglitazone improves recovery of left ventricular function after regional ischemia in pigs. , 2000, Circulation.

[87]  S. Hahn,et al.  Rosiglitazone inhibits Kv4.3 potassium channels by open‐channel block and acceleration of closed‐state inactivation , 2011, British journal of pharmacology.

[88]  J. Auwerx,et al.  Peroxisome proliferator-activated receptor γ, the ultimate liaison between fat and transcription , 2000 .

[89]  Nancy Claude,et al.  Comparative Gene Expression Profiles Induced by PPARγ and PPARα/γ Agonists in Human Hepatocytes , 2011, PloS one.

[90]  L. Heasley,et al.  Antitumorigenic Effects of Peroxisome Proliferator-Activated Receptor-γ in Non-Small-Cell Lung Cancer Cells Are Mediated by Suppression of Cyclooxygenase-2 via Inhibition of Nuclear Factor-κB , 2008, Molecular Pharmacology.

[91]  L. Freedman,et al.  Discrete Roles for Peroxisome Proliferator-Activated Receptor γ and Retinoid X Receptor in Recruiting Nuclear Receptor Coactivators , 2000, Molecular and Cellular Biology.

[92]  D. Pinsky,et al.  Peroxisome proliferator‐activated receptor‐γ (PPAR‐γ) activation suppresses ischemic induction of Egr‐1 and its inflammatory gene targets , 2002 .

[93]  J. Mehta,et al.  The effects of PPAR-gamma ligand pioglitazone on platelet aggregation and arterial thrombus formation. , 2005, Cardiovascular research.

[94]  Armin Ruf,et al.  Comparative Molecular Profiling of the PPARα/γ Activator Aleglitazar: PPAR Selectivity, Activity and Interaction with Cofactors , 2012, ChemMedChem.

[95]  Margaret S. Wu,et al.  Discovery of (2R)-2-(3-{3-[(4-Methoxyphenyl)carbonyl]-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl}phenoxy)butanoic acid (MK-0533): a novel selective peroxisome proliferator-activated receptor gamma modulator for the treatment of type 2 diabetes mellitus with a reduced potential to increase plasma an , 2009, Journal of medicinal chemistry.

[96]  D. Betteridge,et al.  Thiazolidinediones and fracture risk in patients with Type 2 diabetes , 2011, Diabetic medicine : a journal of the British Diabetic Association.

[97]  J. Auwerx,et al.  Peroxisome proliferator-activated receptor gamma, the ultimate liaison between fat and transcription. , 2000, The British journal of nutrition.

[98]  V. Reynolds,et al.  Urothelial Carcinogenesis in the Urinary Bladder of Rats Treated with Naveglitazar, a γ-dominant PPAR α/γ Agonist: Lack of Evidence for Urolithiasis as an Inciting Event , 2008, Toxicologic pathology.

[99]  S. Grundy,et al.  Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003. , 2003, Circulation.

[100]  Julio E. Pérez,et al.  Cardiac and Glycemic Benefits of Troglitazone Treatment in NIDDM , 1997, Diabetes.

[101]  D. Chappard,et al.  Thiazolidinediones Induce Osteocyte Apoptosis by a G Protein-coupled Receptor 40-dependent Mechanism* , 2012, The Journal of Biological Chemistry.

[102]  L. Nagy,et al.  PPARs are a unique set of fatty acid regulated transcription factors controlling both lipid metabolism and inflammation☆ , 2011, Biochimica et biophysica acta.

[103]  A. Chait,et al.  Cardiovascular disease risk in type 2 diabetes mellitus: insights from mechanistic studies , 2008, The Lancet.

[104]  M. Wright,et al.  Examining the safety of PPAR agonists – current trends and future prospects , 2013, Expert opinion on drug safety.

[105]  P. Puigserver,et al.  A Cold-Inducible Coactivator of Nuclear Receptors Linked to Adaptive Thermogenesis , 1998, Cell.

[106]  Sui Huang,et al.  PPARγ as a therapeutic target for tumor angiogenesis and metastasis , 2005 .

[107]  Patrick R. Griffin,et al.  Obesity-linked phosphorylation of PPARγ by cdk5 is a direct target of the anti-diabetic PPARγ ligands , 2010, Nature.

[108]  H P Koeffler,et al.  Ligands for peroxisome proliferator-activated receptorgamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[109]  J. Dixon,et al.  MitoNEET is an iron-containing outer mitochondrial membrane protein that regulates oxidative capacity , 2007, Proceedings of the National Academy of Sciences.

[110]  S. Tafuri,et al.  Regulation of Peroxisome Proliferator-activated Receptor γ Activity by Mitogen-activated Protein Kinase* , 1997, The Journal of Biological Chemistry.

[111]  Ajit S. Divakaruni,et al.  Identification of a Mitochondrial Target of Thiazolidinedione Insulin Sensitizers (mTOT)—Relationship to Newly Identified Mitochondrial Pyruvate Carrier Proteins , 2013, PloS one.

[112]  R. Agrawal.  The first approved agent in the Glitazar's Class: Saroglitazar. , 2014, Current drug targets.

[113]  C. Long,et al.  PPAR-γ activation fails to provide myocardial protection in ischemia and reperfusion in pigs , 2005 .

[114]  T. Bányász,et al.  Effects of rosiglitazone on the configuration of action potentials and ion currents in canine ventricular cells , 2011, British journal of pharmacology.

[115]  A. Lincoff,et al.  Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. , 2007, JAMA.

[116]  B. Seed,et al.  PPAR-γ agonists inhibit production of monocyte inflammatory cytokines , 1998, Nature.

[117]  M. Lambert,et al.  PPAR modulators and PPAR pan agonists for metabolic diseases: the next generation of drugs targeting peroxisome proliferator-activated receptors? , 2008, Current topics in medicinal chemistry.

[118]  K. Umesono,et al.  The nuclear receptor superfamily: The second decade , 1995, Cell.

[119]  G. Bakris,et al.  Protection of the kidney by thiazolidinediones: an assessment from bench to bedside. , 2006, Kidney international.

[120]  B. O’Malley,et al.  Nuclear receptor coregulators: modulators of pathology and therapeutic targets , 2012, Nature Reviews Endocrinology.

[121]  Natalie L. Catlett,et al.  Comparative Transcriptional Network Modeling of Three PPAR-α/γ Co-Agonists Reveals Distinct Metabolic Gene Signatures in Primary Human Hepatocytes , 2012, PloS one.

[122]  I. Blümcke,et al.  PPAR Gamma Activators: Off-Target Against Glioma Cell Migration and Brain Invasion , 2008, PPAR research.

[123]  M. Wick,et al.  Peroxisome Proliferator-Activated Receptor-γ Is a Target of Nonsteroidal Anti-Inflammatory Drugs Mediating Cyclooxygenase-Independent Inhibition of Lung Cancer Cell Growth , 2002 .

[124]  M. van Bilsen,et al.  Peroxisome proliferator-activated receptors (PPARS): regulators of gene expression in heart and skeletal muscle. , 2003, Acta physiologica Scandinavica.

[125]  M. Mogi,et al.  Review Article Role of Peroxisome Proliferator-activated Receptor-γ in Vascular Inflammation , 2022 .

[126]  H P Koeffler,et al.  Ligand for peroxisome proliferator-activated receptor gamma (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo. , 1998, Cancer research.

[127]  M. Serio,et al.  Peroxisome proliferator-activated receptor gamma (PPARγ): Is the genomic activity the only answer? , 2010, Steroids.